Navigation Links
Angiotech to Establish Separate Operating and Royalty Businesses
Date:7/7/2008

other uses of

paclitaxel licensed to BSC and Cook (including uses relating to

Cook's ZILVER(R) PTX paclitaxel-eluting peripheral vascular stent);

(iii) potential royalty and other income from certain other uses of

paclitaxel licensed to Broncus Technologies Incorporated ("Broncus")

relating to the Exhale(R) paclitaxel-eluting lung stent; and (iv)

certain other assets and liabilities not related to the ongoing

business of API. The business of Angiotech prior to the transaction

consists primarily of the business assets to be transferred to API,

and the license agreements with BSC, Cook and Broncus. For the year

ended December 31, 2007, Angiotech had $288 million in revenue, $111

million of which was royalty revenue derived mainly from BSC, and

$177 million of which was product and royalty revenue derived from

the assets to be transferred to API.

- Financing Transaction. The Company has entered into a Note Purchase

Agreement, providing for the issuance and sale of between

$200 million and $300 million of convertible notes to Ares Management

and New Leaf Venture Partners. The convertible notes will have an

initial conversion price of $20 per share, and each $1,000 principal

amount of convertible notes will be convertible into 50 shares of

API, implying an initial equity value for API of $625 million

assuming $75 million in cash and cash equivalents at API at closing

and no debt, other than the guarantees of remaining amounts of

Angiotech's two existing debt issues. The convertible notes will be

convertible into 32% to 48% of the common stock of API, depending

upon the final initial transaction size, calculated on an "if

converted" basis and without taking into account any future dilution

resulting from ad
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014  Franciscan St. Anthony ... capnography for respiratory monitoring outside the operating ... leaders in embracing state-of-the-art patient safety technology. ... are breathing and can alert medical caregivers ... the amount of carbon dioxide the patient ...
(Date:7/10/2014)... -- Kainos Capital, a firm specializing in acquiring and managing ... acquired the Slim-Fast brand from Unilever. Unilever will retain ... transaction were not disclosed. Slim-Fast is a ... ready-to-drink shakes, powders, bars and snacks to retail customers ... the United Kingdom and Ireland.  ...
(Date:7/10/2014)... July 10, 2014 Research and Markets ... the "International Photonic Integrated Circuit (Monolithic Integration, ... 2019" report to their offering. ... concept of photonic integration traces its roots in ... promise of photonic integration went unexplored and unfulfilled ...
(Date:7/10/2014)... -- According to the International Atomic Energy Agency ... from terrorists acquiring sufficient quantities of plutonium or ... nuclear explosive device. The IAEA also notes that ... gram-level quantities, which can be challenging to detect ... new study appearing this week in the ...
Breaking Biology Technology:Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Kainos Capital Acquires Slim-Fast From Unilever 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Sensitive detection method may help impede illicit nuclear trafficking 2
... Ltd. has found that the,Replikin Count(TM) of the H1N1 ... 1.4), its highest level since the 1918 H1N1,pandemic (p ... a particular,influenza strain, indicating rapid replication of the virus, ... an outbreak of the specific,strain. The current increase appears ...
... Kantor joins founding management team to direct ITI,s Center for ... Critical ... Immune Tolerance,Institute Inc., (ITI) today announced that Aaron B. Kantor, Ph.D. ... Louis A. Matis, M.D., President and Chief Executive Officer. Prior to,joining ...
... April 7, 2008 Ardea Biosciences,Inc. (Nasdaq: ... presented on its,second generation non-nucleoside reverse transcriptase inhibitors ... (ICAR).,Additionally, data on two of the Company,s mitogen-activated ... presented at the American,Association for Cancer Research (AACR) ...
Cached Biology Technology:H1N1 Influenza Virus With Highest Replikin Count(TM) Since the 1918 Pandemic Identified in the U.S. and Austria 2Immune Tolerance Institute Appoints Aaron B. Kantor Ph.D. Chief Scientific Officer 2Immune Tolerance Institute Appoints Aaron B. Kantor Ph.D. Chief Scientific Officer 3Immune Tolerance Institute Appoints Aaron B. Kantor Ph.D. Chief Scientific Officer 4Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences 2Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences 3
(Date:7/10/2014)... , July 3, 2014 According ... by Type (Swipe And Area), Material (Optical Prism, Pizeoelectric, ... Commercial Security and Banking & Finance), and Geography - ... by MarketsandMarkets, the global Fingerprint Sensors Market is projected ... high CAGR of 16.8% from 2014 to 2020. ...
(Date:7/10/2014)... July 7, 2014 Fingerprint Cards, (FPC,s) ... design win (DW). A Chinese Top 5 smartphone OEM has ... of mass production in October 2014.   FPC ... 5 smartphone OEM, which has a planned date for the ... sales volume for this phone of 3 million units. The ...
(Date:7/10/2014)... GOTHENBURG, Sweden , July 8, 2014 ... FPC1021 has won a new design win (DW). An Asian ... targeted date for mass production start in August 2014.   ... an Asian smartphone OEM, which has a planned date for ... received an initial ramp order of SEK 5M, for delivery ...
Breaking Biology News(10 mins):Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2
... one key reason why blood stem cells are susceptible to ... Their finding also may explain, they say, why some other ... Cell Stem Cell " (Aug. 6, 2010) and reviewed in ... a new frontier for studying the molecular underpinnings of adult ...
... (August 16, 2010, 9:00 a.m. EDT) A ... promotes angiogenesis, the growth of new blood vessels. ... significantly reduced angiogenesis in mice. These discoveries, published ... Experimental Medicine , may lead to novel treatments ...
... HOUSTON -- (Aug. 16, 2010) -- A new ... and other human activity has completely obscured the natural ... "The natural factors that influence carbon dioxide cycling ... the radiocarbon signature of the river to reflect those ...
Cached Biology News:Blood stem cell, leukemia link illuminated in UCSF-led study 2Blood stem cell, leukemia link illuminated in UCSF-led study 3Scientists reveal new targets for anti-angiogenesis drugs 2A river flipped: Humans trump nature on Texas river 2A river flipped: Humans trump nature on Texas river 3
... to Ki67 - Proliferation Marker, prediluted ... related nuclear protein, expressed by proliferating cells ... cycle (G1, S, G2 and M phase). ... Ki67 antibodies are useful in establishing the ...
Request Info...
Rabbit polyclonal to Aortic Elastin ( Abpromise for all tested applications). entrezGeneID: 2006 SwissProtID: P15502...
Vascular Endothelial Growth Factor C Class: Antibody Product Group: Angiogensis...
Biology Products: